Galderma’s Nemluvio (nemolizumab) is the first IL-31 inhibitor approved by the US Food and Drug Administration for the treatment of atopic dermatitis (AD), bringing a new mechanism of action to patients with the condition. Nemluvio – which is Galderma’s first biologic drug – is already available in the US, having been approved by the FDA in August for the treatment of prurigo nodularis (PN).
Galderma’s Nemluvio Brings New Mechanism To Atopic Dermatitis
Nemluvio is the first IL-31 inhibitor approved by the US FDA for atopic dermatitis and will compete with Sanofi/Regeneron’s Dupixent and other, newer IL-13 inhibitors.
